Study Finds Three Predictors of Pain and Fatigue in Elderly

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

EAST LANSING, Michigan-A study of 841 patients age 65 and older newly diagnosed with breast, colon, lung, or prostate cancer found three predictors of pain and fatigue: advanced stage, more comorbid conditions, and lung cancer, compared with breast cancer (the reference), according to researchers from Michigan State University.

EAST LANSING, Michigan—A study of 841 patients age 65 and older newly diagnosed with breast, colon, lung, or prostate cancer found three predictors of pain and fatigue: advanced stage, more comorbid conditions, and lung cancer, compared with breast cancer (the reference), according to researchers from Michigan State University.

Patients were observed at intake and at 12 to 16, 24 to 30, and 52 weeks. The researchers found that pain and fatigue decreased at each observation over the course of the year of follow-up. Fatigue was more commonly reported than pain (30% vs10%) over the year.

No link was found between advancing age and pain and/or fatigue. After controlling for other variables, women were significantly more likely than men to experience pain and/or fatigue, but this may have been confounded by the fact that the prostate cancer patients were significantly less likely to report either pain or fatigue than the breast patients.

Surgery and radiotherapy were significantly associated with pain and fatigue, and chemotherapy was significantly associated with fatigue, but only within the first 40 days after concluding treatment.

Pain and fatigue correlated with a higher mean number of other symptoms (6 vs 2.5 for those without pain or fatigue). "This fact speaks very strongly to the importance of managing these two symptoms," said lead author Charles Given, PhD (J Pain Symptom Manage 21:456-466, 2001).

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content